Transfusional iron overload is common in hematopoietic SCT (HSCT) patients and is a potential cause of morbidity and mortality. Iron overload, estimated by increased ferritin, appears to be associated with adverse outcomes and decreased survival. [1] [2] [3] [4] There are several unanswered questions in this area. First, it is not clear how to best measure iron overload in these patients. Second, the exact mechanism whereby iron overload causes increased mortality has not been definitively established. Finally, the impact of reducing iron and the best method to achieve iron reduction in these patients are unknown.
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The simplest method to estimate iron overload is by measurement of serum ferritin. However, this strategy is not specific because ferritin is an acute phase reactant and can be elevated in a variety of inflammatory conditions. 5 In the pre-and posttransplant setting, patients may have an elevated ferritin for reasons other than iron overload. Interestingly, a recent study demonstrated that elevated ferritin was associated with decreased survival, but there was no survival impact of iron overload as measured by magnetic resonance imaging (MRI). 6 A meta-analysis also found that there was no association between the iron overload measured by MRI and whilst a serum ferritin of 41000 ng/mL was associated with increased mortality, an even higher ferritin of 42500 ng/mL was not. 7 The 'gold standard' for the measurement of total body iron is the liver biopsy stained with Perls' Prussian blue 8 but MRI is increasingly used to measure the liver iron content and correlates with the liver biopsy. 9 There are two approaches to remove excess iron: phlebotomy and iron chelation. Phlebotomy is generally well tolerated with minimal toxicities and has been used in HSCT patients successfully. 10 We undertook a prospective cohort study in HSCT patients with iron overload to evaluate the safety, feasibility and efficacy of decreasing total body iron by phlebotomy.
Institutional Research Ethics Board approval was obtained to perform this study and all patients provided informed consent. We enrolled patients who were between the ages of 18 and 65 and who were at least 60 days after HSCT. Patients were eligible for the study if they were red cell transfusion independent and had a serum ferritin of at least 1000 μg/L at study entry. Patients underwent phlebotomy of 500 mL of whole blood for 12 procedures. Initially, phlebotomies were done monthly. If the ferritin remained significantly elevated (41000 μg/L) after six phlebotomies, the frequency of phlebotomies was increased to weekly as tolerated. Complete blood count was assessed before each phlebotomy and if the Hb level was o 100 g/L, the phlebotomy was not performed. Iron stores were estimated biochemically by measuring serum ferritin and transferrin saturation levels in each patient before the start of phlebotomy and at 6 and 12 months. Total body iron was estimated from hepatic iron concentration as measured by MRI (signal intensity ratio method) at the same time points. Serum samples were also collected at baseline to screen for the most common mutations of the HFE gene (C282Y and H63D mutations) as hereditary hemochromatosis is common and may contribute to iron overload in HSCT recipients.
The effect of iron overload was studied by laboratory testing of the liver, the heart and the endocrine functions at baseline, 6 and 12 months.
There were 22 patients enrolled in the study between January 2007 and December 2011. The types of transplant included sibling allogeneic (n = 15), matched, unrelated donor (n = 5) and autologous (n = 2). The median number of RBC transfusions before study entry was 38 (range 7-100). Indications for transplant were acute leukemia (n = 11), myelodysplastic syndrome (n = 4), nonHodgkin lymphoma (n = 5), myelofibrosis (n = 1) and aplastic anemia (n = 1). Given that the impact of iron overload in patients who are recipients of auto-HSCT may be different than in patients who receive an allo-HSCT, this analysis is reported only for the allo-HSCT group. Of the 20 allogeneic patients, 14 (70%) were able to complete the series of 12 planned phlebotomies. The reasons for not completing all 12 treatments were relapse (n = 1), extensive GVHD (n = 1), non-compliance (n = 2) and intolerance (n = 2). At baseline, the mean ferritin was 1911.2 μg/L and decreased to 974.7 μg/L at 12 months (P = 0.0001). The mean MRI hepatic iron concentration at baseline was 226.7 μmoL/g and decreased to 157.2 μmoL/g at 12 months (P = 0.0003).
Four patients had an HFE gene mutation. One was homozygous for H63D, two were heterozygous for H63D and one was heterozygous for C282Y.
We were unable to demonstrate an effect of iron reduction on end-organ function using biochemical measurements of organ function.
There are limitations of this study. First, the sample size is small and there were some challenges with recruitment. Given the complicated clinical course that transplant patients undergo, it is sometimes difficult to enroll patients in a study that involves yet another intervention. Second, we were unable to show an effect on organ function. Although biochemical assessment of organ function is simple and noninvasive, it is unlikely to be sufficiently sensitive. Further studies in this area should consider functional assessment of end-organ function, together with longer follow-up. In consideration of the small sample size of this study and the heterogeneity of transplant indications and transplant types, we did not evaluate OS, relapse or non-relapse mortality. Third, we did not evaluate potential confounding factors that may have contributed to elevations in ferritin.
This study demonstrates that early phlebotomy, starting as soon as 60 days post transplant, was feasible, safe and well tolerated in most patients. Phlebotomy was demonstrated to be effective at reducing iron stores with statistically significant reductions in mean ferritin and mean MRI hepatic iron concentration. Given the positive results in this pilot study, we plan to undertake a larger study with longer follow-up using MRI evaluation of iron and phlebotomies to remove excess iron, to determine the effect on morbidity and mortality in this patient population.
